mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 25 01 2022
accepted: 21 09 2022
pubmed: 29 9 2022
medline: 6 12 2022
entrez: 28 9 2022
Statut: ppublish

Résumé

This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients. We performed a single-center prospective study including recently transplanted (< 2 years post-infusion) allogeneic HCT recipients. AEs were assessed through phone calls and graded from 0 to 4, while COVID-19 risk perception was measured using the Brief Illness Perception Questionnaire (BIP-Q5). Fifty-four HCT recipients were evaluated. Incidence and grades of AE (94.4% and 85.2% after the first and second dose, respectively) were similar to those described in the general population. The most common AE was pain at the site of injection. Three patients (5.6%) developed a grade ≥ 3 AE. Vaccine-related cytopenias and graft-versus-host disease flares were not observed. Female sex (OR 3.94, 95% CI 1.14-13.58, p = 0.03) and time since HCT (per month since HCT: OR 1.09, 95% CI 1.01-1.18, p = 0.04) were associated with the occurrence of any AE. The patients' risk perception level of COVID-19 decreased over time (p < 0.05). Our study confirms that the mRNA-1273 SARS-CoV-2 vaccine is safe in recent HCT recipients and suggests that the perceived risk of COVID-19 decreases over time.

Identifiants

pubmed: 36169731
doi: 10.1007/s00520-022-07376-w
pii: 10.1007/s00520-022-07376-w
pmc: PMC9517991
doi:

Substances chimiques

2019-nCoV Vaccine mRNA-1273 EPK39PL4R4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9687-9690

Subventions

Organisme : Fundació la Marató de TV3
ID : 517C/20190318/1330
Organisme : Instituto de Salud Carlos III
ID : FIS PI17/01246
Organisme : Instituto de Salud Carlos III
ID : AGAUR 2017 SGR 865
Organisme : Instituto de Salud Carlos III
ID : Tercel RD16/0011/0028

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Ljungman P, de la Camara R, Mikulska M et al (2021) COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leuk 3510(35):2885–2894. https://doi.org/10.1038/s41375-021-01302-5
doi: 10.1038/s41375-021-01302-5
Sharma A, Bhatt NS, St Martin A et al (2021) Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol 8:e185–e193. https://doi.org/10.1016/s2352-3026(20)30429-4
doi: 10.1016/s2352-3026(20)30429-4 pubmed: 33482113 pmcid: 7816949
Ding Y, Xu J, Huang S et al (2020) Risk perception and depression in public health crises: evidence from the COVID-19 crisis in China. Int J Environ Res Public Heal 17:5728. https://doi.org/10.3390/IJERPH17165728
doi: 10.3390/IJERPH17165728
Fiorillo A, Gorwood P (2020) The consequences of the COVID-19 pandemic on mental health and implications for clinical practice. Eur Psychiatry 63(1):e32. https://doi.org/10.1192/J.EURPSY.2020.35
doi: 10.1192/J.EURPSY.2020.35 pubmed: 32234102
Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416. https://doi.org/10.1056/NEJMoa2035389
doi: 10.1056/NEJMoa2035389 pubmed: 33378609
Pérez-Fuentes MDC, Jurado MDM, Ruiz NFO et al (2020) Questionnaire on perception of threat from COVID-19. J Clin Med 9:1196. https://doi.org/10.3390/JCM9041196
doi: 10.3390/JCM9041196 pubmed: 32331246 pmcid: 7230235
Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life. Med Care 41:582–592. https://doi.org/10.1097/01.MLR.0000062554.74615.4C
doi: 10.1097/01.MLR.0000062554.74615.4C pubmed: 12719681
Le BA, Coste-Burel M, Guillaume T et al (2021) Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant. JAMA Netw Open 4:e2126344–e2126344. https://doi.org/10.1001/JAMANETWORKOPEN.2021.26344
doi: 10.1001/JAMANETWORKOPEN.2021.26344
Ali H, Ngo D, Aribi A et al (2021) Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients. Transplant Cell Ther. 27(11):938.e1-938.e6. https://doi.org/10.1016/J.JTCT.2021.07.008
doi: 10.1016/J.JTCT.2021.07.008 pubmed: 34274492
Chevallier P, Coste-Burel M, Le Bourgeois A et al (2021) Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients. eJHaem 2:520–524. https://doi.org/10.1002/JHA2.242
doi: 10.1002/JHA2.242 pubmed: 34226903 pmcid: 8242867
Matkowska-Kocjan A, Owoc-Lempach J, Chruszcz J et al (2021) The COVID-19 mRNA BNT163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation. Vaccines 9:1209. https://doi.org/10.3390/VACCINES9101209
doi: 10.3390/VACCINES9101209 pubmed: 34696317 pmcid: 8539173
Beatty AL, Peyser ND, Butcher XE et al (2021) Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 4:e2140364–e2140364. https://doi.org/10.1001/JAMANETWORKOPEN.2021.40364
doi: 10.1001/JAMANETWORKOPEN.2021.40364 pubmed: 34935921 pmcid: 8696570
Brewer NT, Weinstein ND, Cuite CL, Herrington JE (2004) Risk perceptions and their relation to risk behavior. Ann Behav Med 27:125–130. https://doi.org/10.1207/S15324796ABM2702_7
doi: 10.1207/S15324796ABM2702_7 pubmed: 15026296
Amonoo HL, Longley RM, El-Jawahri A (2021) The COVID-19 pandemic: unmasking challenges and vulnerability in the HSCT population. J Psychosoc Oncol 39:309–312
doi: 10.1080/07347332.2020.1868647 pubmed: 33468030
Amonoo HL, Topping CEW, Clay MA et al (2021) Distress in a pandemic: association of the coronavirus disease-2019 pandemic with distress and quality of life in hematopoietic stem cell transplantation. Transplant Cell Ther 27(12):1015.e1-1015.e7. https://doi.org/10.1016/J.JTCT.2021.09.001
doi: 10.1016/J.JTCT.2021.09.001 pubmed: 34536571

Auteurs

Nil Albiol (N)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. nilalbiol@iconcologia.net.
Institut d'Investigació Biomèdica (IIB) Sant Pau, Barcelona, Spain. nilalbiol@iconcologia.net.
Autonomous University of Barcelona, Barcelona, Spain. nilalbiol@iconcologia.net.
Josep Carreras Leukaemia Research Institute, Barcelona, Spain. nilalbiol@iconcologia.net.

Olga Aso (O)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Lucía Gómez-Pérez (L)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Mercè Triquell (M)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Nerea Roch (N)

Infectious Diseases Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Elisabeth Lázaro (E)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Albert Esquirol (A)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
Institut d'Investigació Biomèdica (IIB) Sant Pau, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.
Josep Carreras Leukaemia Research Institute, Barcelona, Spain.

Iria González (I)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Joaquín López-Contreras (J)

Autonomous University of Barcelona, Barcelona, Spain.
Infectious Diseases Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Jorge Sierra (J)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
Institut d'Investigació Biomèdica (IIB) Sant Pau, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.
Josep Carreras Leukaemia Research Institute, Barcelona, Spain.

Rodrigo Martino (R)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
Institut d'Investigació Biomèdica (IIB) Sant Pau, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.
Josep Carreras Leukaemia Research Institute, Barcelona, Spain.

Irene García-Cadenas (I)

Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. igarciaca@santpau.cat.
Institut d'Investigació Biomèdica (IIB) Sant Pau, Barcelona, Spain. igarciaca@santpau.cat.
Autonomous University of Barcelona, Barcelona, Spain. igarciaca@santpau.cat.
Josep Carreras Leukaemia Research Institute, Barcelona, Spain. igarciaca@santpau.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH